人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2019.180

摘要/Abstract

摘要： 目的探讨人源性长寿保障基因2(LASS2)在结直肠癌组织中的表达及其临床意义。方法选取2011年8月至2013年8月结直肠癌患者85例,免疫组化(SP法)检测结直肠癌和癌旁组织中LASS2蛋白表达,术后随访,随访截止日期为2018年8月30日,78例患者得到完整随访,随访率91.76%。生存分析采用Kaplan-Meier法和Log-rank检验,患者预后的影响因素分析采用Cox比例风险回归模型。结果 LASS2蛋白在结直肠癌组织中阳性表达率(32.94% vs 78.82%,P<0.001)低于癌旁组织。LASS2蛋白在中低分化、TNM分期Ⅲ+Ⅳ期和发生淋巴结转移的结直肠癌组织中阳性表达率低于高分化、TNM分期Ⅰ+Ⅱ期和未发生淋巴结转移的结直肠癌组织(P<0.05);LASS2蛋白阳性表达组患者总生存时间(57.60个月 vs 28.47个月, P<0.001)及累积生存率(55.60% vs 19.60%,P<0.001)高于LASS2蛋白阴性表达组。分化程度、TNM分期、淋巴结转移和LASS2蛋白表达是影响结直肠癌患者预后的风险因素(HR=0.134、2.907、2.478、0.476,P<0.05)。结论 LASS2蛋白在结直肠癌患者组织中呈低表达,且与患者恶性化进展及预后有关,可能是结直肠癌患者预后评估的潜在生物标志物。

关键词: 结直肠癌, 人源性长寿保障基因2, 预后, Cox比例风险回归模型

Abstract: Objective To investigate the expression and clinical significance of homo sapiens longevity assurance homologue 2 of yeast LAG1(LASS2)in colorectal cancer. Methods A total of colorectal cancer 85 cases treated during Aug. 2011 and Aug. 2013 were involved. The protein expression of LASS2 in colorectal cancer and adjacent tissues were detected with immunohistochemistry(SP method). All patients were followed up, and until Aug. 30, 2018, the complete follow-up data of 78(91.76%)cases were obtained. Patients’ survival was analyzed using Kaplan-Meier method and Log-rank test. The influencing factors on prognosis were determined with Cox proportional hazards regression model. Results The positive expression rates of LASS2 in colorectal cancer tissues and adjacent tissues was 32.94% vs 78.82%(P<0.001). The positive expression rates of LASS2 in colorectal cancer tissues with moderately poor differentiation, TNM stage Ⅲ+Ⅳ and lymph node metastasis were lower than that in high differentiation, TNM stage Ⅰ+Ⅱ and without lymph node metastasis(P<0.05). The overall survival of patients with positive versus negative LASS2 expression was 57.60 vs 28.47 months(P<0.001), and cumulative survival rate was 55.60% vs 19.60%(P<0.001). The differentiation, TNM stage, lymph node metastasis and protein expression of LASS2 were influencing factors on the 山东大学学报 (医学版)57卷7期 -郭艳,等.人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义 \=-prognosis(HR=0.134, 2.907, 2.478 and 0.476, P<0.05). Conclusion LASS2 is lowly expressed in colorectal cancer tissues, and is related to the malignant progression and prognosis. It might be a potential biomarker for prognosis assessment.

Key words: Colorectal cancer, Homo sapiens longevity assurance homologue 2 of yeast LAG1, Prognosis, Cox proportional hazard regression model

中图分类号:

R735.3

郭艳,张哲莹,王云溪,魏小娟. 人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义[J]. 山东大学学报 (医学版), 2019, 57(7): 67-71.

8.GUO Yan, ZHANG Zheying, WANG Yunxi, WEI Xiaojuan. Expression and clinical significance of homo sapiens longevity assurance homologue 2 of yeast LAG1 in colorectal cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 67-71.

参考文献

[1] Murphy CC, Wallace K, Sandler RS, et al. Racial disparities in incidence of young-onset colorectal cancer and patient survival [J]. Gastroenterology, 2019, 156(4): 958-965.
[2] Pang QY, An R, Liu HL. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis [J]. World J Surg Oncol, 2019, 17(1): 7-13.
[3] 刘童, 张欣, 王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报(医学版), 2016, 54(7): 69-74, 87. LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. Journal of Shandong University(Health Sciences), 2016, 54(7): 69-74, 87.
[4] 张静, 王晰程, 沈琳. 分子标志物对Ⅱ期和Ⅲ期结直肠癌术后随访策略的影响[J]. 中华胃肠外科杂志, 2018, 21(6): 716-720. ZHANG Jing, WANG Xicheng, SHEN Lin. Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage Ⅱ and Ⅲ colorectal cancer [J]. Chinese Journal of Gastrointestinal Surgery, 2018, 21(6): 716-720.
[5] Yegin Z, Aydin O, Koc H, et al. Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer [J]. Cell Mol Biol(Noisy-le-grand), 2018, 64(11): 66-73.
[6] 左华楚, 李秀霞, 李时荣, 等. LSAA2/TMSG-1基因沉默对人肺癌95C细胞侵袭迁移机制探讨[J]. 中华肿瘤防治杂志, 2015, 22(24): 1865-1873. ZUO Huachu, LI Xiuxia, LI Shirong, et al. Effect of LASS2/TMSG on the invasion and migration of 95C human pulmonary carcinoma cell [J]. Chinese Journal of Cancer Prevention and Treatment, 2015, 22(24): 1865-1873.
[7] 王鑫, 王忠臣, 孙微微. 血管生成素样蛋白1在结直肠癌中表达的意义及对其生物学行为的影响[J]. 中华普通外科杂志, 2018, 33(4): 326-329. WANG Xin, WANG Zhongchen, SUN Weiwei. Clinicopathological significance and biological behavior of ANGPTLl expression in human colorectal cancer [J]. Chinese Journal of General Surgery, 2018, 33(4): 326-329.
[8] Zhang S, Yang Y, Yan D, et al. Internet videos and colorectal cancer in mainland China: a content analysis [J]. BMC Med Inform Decis Mak, 2018, 18(1): 129-137.
[9] Ott C, Gerken M, Hirsch D, et al. Advanced mucinous colorectal cancer: epidemiology, prognosis and efficacy of chemotherapeutic treatment [J]. Digestion, 2018, 98(3): 143-152.
[10] Gan T, Sinner HF, Walling SC, et al. Impact of the affordable care act on colorectal cancer screening, incidence, and survival in Kentucky [J]. J Am Coll Surg, 2019, 228(4): 342-353.
[11] 刘铭, 王崑, 包全, 等. 肝转移灶个数对结直肠癌肝转移患者术后生存的影响[J]. 中华普通外科杂志, 2018, 33(1): 34-37. LIU Ming, WANG Kun, BAO Quan, et al. Effect of tumor number on the survival of patients of colorectal cancer liver metastases undergoing hepatic resection [J]. Chinese Journal of General Surgery, 2018, 33(1): 34-37.
[12] 朱宇, 王宏洁, 韩彬彬, 等. 人异常凝血酶原(PIVKA-II)在监测结直肠癌肝转移中的应用[J]. 山东大学学报(医学版), 2018, 56(10): 58-63. ZHU Yu, WANG Hongjie, HAN Binbin, et al. A study of serum PIVKA-II in patients with liver metastasis of colorectal cancer [J]. Journal of Shandong University(Health Sciences), 2018, 56(10): 58-63.
[13] Kim H, Jung HI, Kwon SH, et al. Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis [J]. Ann Surg Treat Res, 2019, 96(4): 191-200.
[14] Wang H, Zuo Y, Ding M, et al. LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity [J]. Oncol Lett, 2017, 13(2): 661-668.
[15] Mei F, You J, Liu B, et al. LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity [J]. Tumour Biol, 2015, 36(4): 2831-2844.
[16] Fan SH, Wang YY, Wu ZY, et al. AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer [J]. Oncotarget, 2015, 6(21): 18406-18417.
[17] Zou P, Yang Y, Xu X, et al. Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner [J]. Oncol Rep, 2018, 39(1): 298-306.
[18] Yang Y, Yang X, Li L, et al. LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor?κB pathways [J]. Oncol Rep, 2019, 41(5): 3005-3014.
[19] 袁远, 黄恩应, 陈小刚. LASS2在膀胱癌组织中的表达及对细胞增殖和侵袭能力的影响[J]. 福建医科大学学报, 2018, 52(5): 311-315.
[20] 李时荣, 伊日贵, 左华楚, 等. 人类长寿保障基因2/肿瘤转移抑制基因1基因过表达对人肺癌细胞的影响[J]. 中华实验外科杂志, 2017, 34(7): 1252-1253. LI Shirong, YI Rigrui, ZUO Huachu, et al. Effects of homo sapiens longevity assurance homologue 2/tumor metastasis suppressor gene 1 gene overexpression on human lung cancer cells [J]. Chinese Journal of Experimental Surgery, 2017, 34(7): 1252-1253.
[21] Wang H, Zuo Y, Ding M, et al. LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity [J]. Oncol Lett, 2017, 13(2): 661-668.
[22] Gu D, Jin H, Jin G, et al. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity [J]. Cancer Lett, 2016, 379(1): 107-116.
[23] Ke RH, Wang Y, Mao Y, et al. Decreased expression of LASS2 is associated with worse prognosis in meningiomas [J]. J Neurooncol, 2014, 118(2): 369-376.
[24] Ruan H, Wang T, Yang C, et al. Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma [J]. Sci Rep, 2016, 6(9): 1-9.
[25] Sheng N, Wang Y, Xie Y, et al. High expression of LASS2 is associated with unfavorable prognosis in patients with ovarian cancer [J]. J Cell Physiol, 2019, 234(8): 13001-13013.

相关文章 15

[1]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	王刚,徐鹏演,赵旭安,王海锋,葛苗苗,潘华峰,江志伟. ω-3多不饱和脂肪酸对腹腔镜结直肠癌术后迷走神经和肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(2): 36-42.
[8]	崔倩倩,李金鹏,吴豫丹,侯志平,孙玮螺,崔盼盼,何培元. 粪便miRNA对结直肠进展期腺瘤无创筛查的临床价值[J]. 山东大学学报 (医学版), 2025, 63(2): 43-50.
[9]	常宇,胡云峰,王会丰,郭静,张跳,郝雅琴,刘雨. 阑尾切除术与结直肠癌发病风险关联的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2025, 63(2): 77-83.
[10]	俞静,王刚,王烨,邵明月,潘华峰,葛苗苗,王海锋,江志伟. 基于I-FEED评分系统观察益气导滞方对结直肠癌术后胃肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(12): 35-43.
[11]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[12]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[13]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[14]	王潇,孔文茹,崔伟亮,王姝麒. 羊角棉总生物碱增强氟尿嘧啶对结直肠癌化疗敏感性[J]. 山东大学学报 (医学版), 2024, 62(6): 30-37.
[15]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed